<DOC>
	<DOCNO>NCT02616211</DOCNO>
	<brief_summary>Patients ask participate study diagnose thoracic carcinoma include lung cancer gene mutation ( alteration body 's genetic instruction ) undergo treatment cancer come back , progress , show partial response standard treatment .</brief_summary>
	<brief_title>An Integrated Approach Treating Recurrent Thoracic Carcinomas Resistant Tyrosine Kinase Inhibitors</brief_title>
	<detailed_description>In order improve treatment outcome thoracic carcinomas become resistant targeted therapy , investigator use tumor biopsy time recurrence genomic analysis identify novel somatic change critical gene gene pathway potentially targeted therapy . The study team also create patient-derived xenografts test drug efficacy optimize personalized therapy patient .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>18 year old Thoracic carcinoma tumor positive targetable genetic alteration Have show partial response , progression recurrence gene target therapy CT/PET scan Tumor accessible biopsy surgery Expected life 6 month longer . &lt; 18 year Not able communicate English</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>